No Data
No Data
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat With Azacitidine to Treat Hematologic Cancers
Express News | Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-Initiated Phase 1/2 Clinical Trial Using Seclidemstat With Azacitidine to Treat Hematologic Cancers
Salarius Pharmaceuticals Files to Sell Common Stock, Warrants, No Amount Given
Shareholder Alert: Ademi LLP Investigates Whether Salarius Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
12 Health Care Stocks Moving In Monday's Pre-Market Session
Sector Update: Health Care